MRG002 antibody compared with standard chemo for HER2 bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial studies whether MRG002, a targeted antibody treatment, works better than the patient’s chosen standard chemotherapy. It is for people with HER2-positive advanced or metastatic urothelial (bladder/urinary tract) cancer whose disease has progressed after prior platinum chemotherapy and immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be willing to sign consent and follow the study visit and treatment plan.
- Age 18 to 75, and expected to live at least 12 weeks.
- Have unresectable locally advanced or metastatic urothelial cancer confirmed by tissue biopsy.
- Your tumor must be HER2-positive (tested as IHC 3+ or IHC 2+) by a central lab.
- Cancer must have progressed after prior platinum chemotherapy and PD-1/PD-L1 immune therapy.
- Provide a tumor sample (from a biopsy or stored tissue) and have at least one measurable lesion on scans.
- Be well enough to do daily activities (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
This trial tests a new drug, SHR-A2102, against the usual treatments for people with advanced bladder cancer that has spread. It is for those whose cancer has worsened after platinum chemotherapy and immunotherapy.
This trial tests a new drug called MRG007 combined with other treatments for people with advanced colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the combination is safe and effective.
This trial uses a special PET/CT scan to see if your bladder cancer has HER2 proteins, which can help predict how well you will respond to a targeted antibody-drug conjugate treatment. It is for people with advanced bladder cancer who have already tried certain standard therapies.
This trial tests a new combination of two medications, SHR-A2102 and adebrelimab, for people with advanced bladder cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug called BL-M07D1 for people with certain advanced solid tumors that have the HER2 protein (high or low amounts). The goal is to see if it can shrink or slow the growth of these cancers, especially in urinary and digestive system tumors.
Hear when a new Advanced or Metastatic Urothelium Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.